Literature DB >> 16774656

Health resource utilization associated with switching to risperidone long-acting injection.

C L Young1, D M Taylor.   

Abstract

OBJECTIVE: Studies have shown oral risperidone and conventional depot antipsychotics decrease direct healthcare costs largely by reducing hospitalization. Our aim was to assess the effect on bed stay of risperidone injection prescribed in normal clinical practice.
METHOD: Patients prescribed risperidone long-acting injection (RLAI) were identified and followed-up for 1 year. Resource use data were collected for 3 years before and for 1 year after the initiation of RLAI. The main outcome measure was bed stay before and after the prescription of RLAI.
RESULTS: Outcome data were available for 250 subjects. Eighty-one subjects (32.4%) completed 1 year's treatment. Days spent in hospital increased from (mean number/patient) 31 in year -3 to 44 in year -2 to 90 in year -1 to 141 in year +1. Direct healthcare costs increased accordingly. Outcome for RLAI continuers was similar to that of discontinuers.
CONCLUSION: Switching to RLAI was associated with a continuation of the trend for increased bed stay and use of healthcare resources.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16774656     DOI: 10.1111/j.1600-0447.2006.00766.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  12 in total

Review 1.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Five-year patient outcomes with risperidone long-acting injection or oral aripiprazole.

Authors:  Paul Nicholas Deslandes; Matthew Dwivedi; Robert D E Sewell
Journal:  Ther Adv Psychopharmacol       Date:  2015-06

3.  Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.

Authors:  Christopher Carswell; Amanda Wheeler; Jane Vanderpyl; Elizabeth Robinson
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 4.  Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.

Authors:  Hans-Jürgen Möller
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia.

Authors:  Xiaomei Peng; Haya Ascher-Svanum; Douglas Faries; Robert R Conley; Kory J Schuh
Journal:  Clinicoecon Outcomes Res       Date:  2011-01-11

7.  Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).

Authors:  Concetta Crivera; Cherilyn DeSouza; Chris M Kozma; Riad D Dirani; Lian Mao; Wayne Macfadden
Journal:  BMC Psychiatry       Date:  2011-10-14       Impact factor: 3.630

8.  Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization.

Authors:  David Taylor; Olubanke Olofinjana
Journal:  Int Clin Psychopharmacol       Date:  2014-07       Impact factor: 1.659

9.  A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates.

Authors:  Daniel Bressington; Jon Stock; Sabina Hulbert; Douglas MacInnes
Journal:  Int Clin Psychopharmacol       Date:  2015-07       Impact factor: 1.659

10.  Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia.

Authors:  Annie Viala; Françoise Cornic; Marie-Noëlle Vacheron
Journal:  Schizophr Res Treatment       Date:  2012-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.